Photobiomodulation for Parkinson's (NCT07271927)
Improve motor and cognitive function
- Trial ID
- NCT07271927
- Official Title
- Evaluation Study of the Effects and Safety of Whole-Body Photobiomodulation Therapy on Motor and Cognitive Changes in Patients With Parkinson's Disease
- Goal
- Improve motor and cognitive function
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Pusan National University Yangsan Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 15 participants
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- Photobiomodulation
Summary For Families
The trial wants to find out whether whole-body photobiomodulation can improve movement and thinking problems in people with Parkinson's, while checking that the treatment is safe. Photobiomodulation uses low-level red and near-infrared light applied to the body to stimulate mitochondria, boost cellular energy (ATP), and reduce inflammation and oxidative stress, which may protect neurons and help motor and cognitive function; it is a non-drug therapy meant to be used alongside standard medications like levodopa, not to replace them. Adults aged 40 and up with Parkinson's at Hoehn and Yahr stages 1 to 3 who can walk independently are eligible, while people with very severe cognitive impairment (K-MMSE ≤ 9), implanted electronic devices, a history of seizures or serious psychiatric or medical issues, pregnancy, or recent participation in multiple trials are excluded.
Locations
- Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-do, South Korea
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Photobiomodulation. The trial wants to find out whether whole-body photobiomodulation can improve movement and thinking problems in people with Parkinson's, while checking that the treatment is safe. Photobiomodulation uses low-level red and near-infrared light applied to the body to stimulate mitochondria, boost cellular energy (ATP), and reduce inflammation and oxidative stress, which may protect neurons and help motor and cognitive function; it is a non-drug therapy meant to be used alongside standard medications like levodopa, not to replace them. Adults aged 40 and up with Parkinson's at Hoehn and Yahr stages 1 to 3 who can walk independently are eligible, while people with very severe cognitive impairment (K-MMSE ≤ 9), implanted electronic devices, a history of seizures or serious psychiatric or medical issues, pregnancy, or recent participation in multiple trials are excluded.
- Who can participate?
- Participants must be at least 40 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 10 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- Everyone in this trial receives the experimental treatment. There is no placebo group.
- How many visits does this trial involve?
- You will have 30 therapy sessions over approximately 10 weeks, about three sessions per week, each session 20 minutes long.